NCT00078455已完成2 期
A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Genzyme, a Sanofi Company20 个研究点 分布在 1 个国家开始时间: 2003年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 20
研究概览
简要总结
This is a Phase II, non-randomized, open label study of ILX651 in patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC). Approximately 60 patients will be enrolled in this study that is expected to last 18 months. All patients will be treated with ILX651 administered intravenously (IV) daily for 5 consecutive days once every 21 days. The primary objective of this study is to determine the overall response rate. The secondary objectives are to determine the progression free survival, duration of response, time to tumor progression, survival, safety/tolerability of ILX651, and to evaluate pharmacokinetic profile.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed locally advanced or metastatic NSCLC previously treated with 2 prior chemotherapy regimens (not including prior adjuvant therapy for stage I or II disease).
- •Disease recurrence or progression after prior therapy with a platinum-based and a taxane-based regimen, given either concurrently or separately.
- •Measurable disease. Measurable lesions should be outside the field of radiation. Where measurable lesions are within a previously irradiated field, there must be objective evidence of progression of the lesion prior to patient enrollment.
- •Male or female patients greater than or equal to 18 years of age.
- •ECOG performance status of 0 or
- •Must have adequate organ and immune system function as indicated by the following laboratory values, obtained less than or equal to 2 weeks prior to registration: A. Absolute neutrophil count (ANC) greater than or equal to 1.5 x 1,000,000,
- •B. Hemoglobin greater than or equal to 9.0 g/dL. C. Platelet count greater than or equal to 100 x 1,000,000,000/L. D. Serum creatinine or calculated creatinine clearance less than or equal to 1.5 mg/dL or greater than or equal to 60 mL/min. E. Serum total bilirubin within limits of normal values. F. AST and ALT less than or equal to 2 times the upper limit of normal (ULN). G. Alkaline phosphatase within limits of normal values
- •Anti-cancer therapy, major surgery, or irradiation must have been completed at least 3 weeks before enrollment in this study. Patient must have recovered from the acute side effects incurred as a result of previous therapy.
- •Female patients with childbearing potential must have a negative pregnancy test within 7 days of study enrollment. Men and women of reproductive potential must use an effective contraceptive method while enrolled in the study.
- •Signed informed consent (includes HIPAA authorization).
排除标准
- •Patients with uncontrolled congestive heart failure or angina, patients with a history of myocardial infarction within 2 months of enrollment, or patients with cardiac functional capacity Class III or IV as defined by the New York Heart Association Classification.
- •Previously treated with > 2 prior chemotherapy regimens for advanced or metastatic disease.
- •Prior radiotherapy to the only site of measurable disease.
- •Known hypersensitivity to study drug or its analogs.
- •Use of investigational agents within previous 30 days.
- •Known, active infection, or known HIV positive or presence of an AIDS related illness.
- •Active secondary malignancy except minor skin cancers.
- •Presence of symptomatic active brain metastases, including leptomeningeal involvement.
- •Any significant concurrent disease or illness, or psychiatric disorders or alcohol or chemical abuse that would, in the opinion of the investigator, compromise patient safety or compliance, or interfere with the interpretation of study results.
- •Pregnant or lactating females.
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic MelanomaMelanomaNCT00068211Genzyme, a Sanofi Company
已完成
2 期
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With DocetaxelHormone-refractory Prostate CancerNCT00082134Genzyme, a Sanofi Company40
进行中（未招募）
1 期
Gene Therapy for ACM Due to a PKP2 Pathogenic VariantArrhythmogenic CardiomyopathyPKP2-ACMPKP2-ARVCNCT06109181Lexeo Therapeutics10
招募中
2 期
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain MetastasesAdvanced GlioblastomaMetastatic Melanoma in the Central Nervous SystemMGMT-Unmethylated GlioblastomaNCT05909618Sheba Medical Center33
已完成
2 期
A Study in Participants With Acute LeukemiaLeukemiaNCT01214603Eli Lilly and Company20